// App-Quantinova.ai

: Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study

Researchers

Presenter

  • Laurie H Sehn

Principal Investigators

  • Alex F. Herrera

  • Matthew J Matasar

  • Manali Kamdar

  • Sarit Assouline

  • Mark Hertzberg

  • Tae Min Kim

  • Won-Seog Kim

  • Andrew McMillan

  • Muhit zcan

  • Jamie M Hirata

  • Elicia Penuel

  • Ji Cheng

  • Grace Ku

  • Christopher R Flowers

Medical Centers

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • City of Hope, Duarte, CA

  • Memorial Sloan Kettering, New York, NY

  • University of Colorado Hospital, Aurora, CO

  • Montreal University, Montreal, QC, Canada

  • Department of Haematology,Prince of Wales Hospital,Sydney,Australien

  • Chonbuk National University Medical School, Jeonju, Korea, Republic of

  • Samsung Medical Center, seoul, CA, Korea, Republic of (South)

  • Nottingham City Hospital, Nottingham, United Kingdom

  • Ankara University, Ankara, Turkey

  • Genentech, Inc., South San Francisico, CA

  • Hoffmann-La Roche Ltd, Mississauga, ON, Canada

  • Department of Bone Marrow and Stem Cell Transplantation, Winship Cancer Institute of Emory University, Atlanta, GA

Locations

  • Canada

  • United States

  • Australia

  • Republic of South Korea

  • United Kingdom

  • Turkey

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Lymphomas

Biomarkers

  • B-cell lymphoma 2

  • cMYC

Drug/Treatment

  • Polatuzumab vedotin

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Bendamustine

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

  • Cohort

Phase

  • I/II

Study Id's

  • NCT02257567

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved